Article Sidebar
Published:
Jun 2, 2017DOI:
10.4314/tjpr.v16i5.1Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Formulation and development of colon-targeted mucopenetrating metronidazole nanoparticles
Abstract
Purpose: To formulation and develop colon-targeted mucopenetrating metronidazole nanoparticles.
Methods: Metronidazole-loaded chitosan nanoparticles with a pH-sensitive polymer, hydroxyl propyl methyl cellulose phthalate (HPMCP), were prepared by ionic gelation technique and then coated with Eudragit S100 by solvent evaporation method. The nanoparticles were optimized using one variable at a time (OVAT) approach. Further, the nanoparticles were evaluated by scanning electron microscopy (SEM) and zeta sizer, as well as for in-vitro release. Muco-adhesion was evaluated by modified bioadhesion detachment force measurement balance and muco-penetration of fluorescein isothiocyanate (FITC) labeled optimized nanoparticles was determined by microscopic technique
Results: Morphological assessment results revealed smooth, spherical particles with homogeneous distribution and polydispersity index (PDI) of 0.213. The optimized formulation showed particle size of 202 ± 27 nm, zeta potential of 26.9 ± 2.4 mV as well as and entrapment efficiency of 79 ± 5.4 %. There was significant difference in drug release between coated (8.46 ± 2.49 %) and uncoated (28.96 ± 4.04%) nanoparticles at the 5th h in simulated gastric conditions. Muco-adhesion data revealed that uncoated nanoparticles (14.98 x 103 dyne/cm2) showed higher muco-adhesion detachment force compared to coated (12.34 x 103 dyne/cm2) nanoparticles. Muco-penetration results confirm the retention (for up to 12 h) of the developed formulation at the target site for enhanced therapeutic exposure of the entrapped drug.
Conclusion: Eudragit S100 coating of chitosan-HPMCP nanoparticles promotes efficient drug targeting and thus provides a strategy for treating mucosal infections. .
Keywords: Metronidazole, pH-sensitive nanoparticles, Hydroxylpropyl methylcellulose phthalate, Ionic gelation, Mucoadhesion, Mucopenetration, Intestinal infection
